查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球神经内分泌肿瘤治疗市场——行业规模、份额、趋势、竞争、机会、2018-2028 年预测、按产品分析、按站点分析、按最终用户、按地区、按竞争对手
市场调查报告书
商品编码
1244132

全球神经内分泌肿瘤治疗市场——行业规模、份额、趋势、竞争、机会、2018-2028 年预测、按产品分析、按站点分析、按最终用户、按地区、按竞争对手

Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球神经内分泌肿瘤治疗市场预计将在 2024-2028 年的预测期内升级。

这是由于全球神经内分泌肿瘤的患病率不断上升。 根据 2022 年 4 月的癌症杂誌文章“胃肠胰神经内分泌肿瘤 (GEP-NENs) 的诊断和治疗管理进展”，神经内分泌肿瘤的发病率在过去 30 至 40 年中显着增加。 1型神经纤维瘤病（NF1）、结节性硬化症（TSC）病、1型多发性内分泌肿瘤（MEN1）、2型多发性内分泌肿瘤（MEN2）、Von Hippel-Lindau综合征（VHL）神经内分泌肿瘤 (NET)。 根据 2022 年 2 月更新的最新美国临床肿瘤学会神经内分泌肿瘤统计数据，在美国，每年有超过 12,000 人被诊断出患有神经内分泌肿瘤，约有 175,000 人患有神经内分泌肿瘤。

加大政府力度

美国等许多发达国家的政府都在为癌症研究寻求资金，以帮助诊断和治疗癌症。 它还赞助了许多临床试验，以帮助公司开发癌症治疗方法。 例如，截至 2021 年 4 月，对确保无癌未来至关重要的癌症研究的联邦资助已从美国国家癌症研究所获得约 1.1 亿美元的研究资助。 此外，在 2021 年罕见癌症、罕见疾病和未满足需求 (RCRDUN) 资助机会中，澳大利亚联邦卫生部在 2022 年 1 月承诺拨款 6340 万美元用于罕见癌症和罕见疾病的研究。我们宣布，我们已准备就绪. 此外，弗林德斯大学还获得了 23.742 亿美元的资金，其中包括用于“实施护士支持的共享护理模式以解决神经内分泌肿瘤患者未满足的需求：AUS-NET 试验”项目。 神经内分泌肿瘤研究基金会 (NETRF) 也投资了 150 万美元用于开发先进的放射疗法——□受体放射性核素疗法 (PRRT)。

各公司采取的措施

该行业的许多参与者正在采用合作伙伴关係和协作、新产品发布、与分销相关的协议以及地域扩张等战略来确立其市场地位。 例如，2018 年 6 月，勃林格殷格翰宣布投资 2.7 亿美元建设一个新的生物製剂开发中心 (BDC)，该中心不仅致力于免疫学，也致力于免疫肿瘤学。 此外，2018 年 1 月，Novartis AG 宣布从其子公司 Novartis Groupe France S.A. 购买所有普通股，包括 Advanced Accelerator Applications S.A. (AAA)。

近期发展

  • Aerium Therapeutics Inc 将于 2022 年 6 月开始运营，提供 2650 万美元（2500 万欧元）的资金用于低级别和高级神经内分泌肿瘤的系统靶向放射治疗和诊断。
  • Ipsen SA 于 2022 年 3 月为 Somatuline Autogel/Somatuline Depot（兰瑞□）投资了一款全新的最先进电子自动注射器，以推进该类别的创新并提升患者的给药和注射体验。底部。 这种自动注射器旨在改善类癌综合征、肢端肥大症或胃肠胰神经内分泌肿瘤患者的体验。
  • Belzutifan (Welireg) 是一种缺氧诱导因子抑製剂，适用于患有 von Hippel-Lindau 病的成年人，于 2021 年 8 月获得 FDA 批准。

市场细分

全球神经内分泌肿瘤治疗市场根据产品分析、地点分析、最终用户、地区和公司进行细分。 根据产品分析，市场可细分为生长抑素类似物 (SSA)、靶向疗法等。 根据现场分析，市场分为肺、胰腺、结肠、小肠等。 基于最终用户，市场分为医院和诊所、门诊护理中心等。

公司简介

在全球神经内分泌肿瘤治疗市场上运营的主要竞争对手包括 F Hoffmann-La Roche AG、Bristol-Myers Squibb Co、Eli Lilly & Co、Novartis AG、Pfizer Inc、Amgen Inc、Exelixis Inc、Teva 这些包括 Pharmaceutical Industries Ltd、AVEO Pharmaceuticals Inc 和 Hutchison MediPharma Ltd.

报告范围：

本报告将全球神经内分泌肿瘤市场分为以下几类，以及下面详述的行业趋势：

神经内分泌肿瘤市场，按产品分析：

  • 生长抑素类似物 (SSA)
  • 靶向治疗
  • 其他

神经内分泌肿瘤市场，网站分析：

  • 肺
  • 胰腺
  • 大肠
  • 小肠
  • 其他

最终用户的神经内分泌肿瘤治疗市场：

  • 医院和诊所
  • 门诊中心
  • 其他

神经内分泌肿瘤治疗市场，按地区划分：

  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚
  • 欧洲
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙
  • 北美
    • 美国
    • 墨西哥
    • 加拿大
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
  • 中东和非洲
    • 南非
    • 沙特阿拉伯
    • 阿联酋

竞争格局

公司概况：对全球神经内分泌肿瘤治疗市场主要参与者的深入分析。

可自定义：

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势概述

第 4 章 VOC（客户之声）

第5章临床试验分析

  • 正在进行的临床试验
  • 已完成临床试验
  • 已完成临床试验
  • 管道细分（按开发阶段）
  • 管道细分（按状态
  • 管道故障，按站点分析
  • 按地区划分的渠道细分
  • 临床试验热图

第 6 章神经内分泌肿瘤的全球市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按产品分析（生长抑素类似物 (SSA)、靶向疗法、其他）
    • 部位分析（肺、胰腺、大肠、小肠等）
    • 按最终用户（医院/诊所、门诊诊所、其他）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 按产品分析
    • 通过站点分析
    • 最终用户
    • 按地区

第 7 章亚太地区神经内分泌肿瘤治疗市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按产品分析（生长抑素类似物 (SSA)、靶向疗法、其他）
    • 部位分析（肺、胰腺、大肠、小肠等）
    • 按最终用户（医院/诊所、门诊诊所、其他）
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第八章欧洲神经内分泌肿瘤药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按产品分析（生长抑素类似物 (SSA)、靶向疗法、其他）
    • 部位分析（肺、胰腺、大肠、小肠等）
    • 按最终用户（医院/诊所、门诊诊所、其他）
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第九章北美神经内分泌肿瘤药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按产品分析（生长抑素类似物 (SSA)、靶向疗法、其他）
    • 部位分析（肺、胰腺、大肠、小肠等）
    • 按最终用户（医院/诊所、门诊诊所、其他）
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 墨西哥
    • 加拿大

第10章南美神经内分泌肿瘤药物市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按产品分析（生长抑素类似物 (SSA)、靶向疗法、其他）
    • 部位分析（肺、胰腺、大肠、小肠等）
    • 按最终用户（医院/诊所、门诊诊所、其他）
    • 按国家
  • 南美洲：：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章中东和非洲神经内分泌肿瘤药物的市场前景

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按产品分析（生长抑素类似物 (SSA)、靶向疗法、其他）
    • 部位分析（肺、胰腺、大肠、小肠等）
    • 按最终用户（医院/诊所、门诊诊所、其他）
    • 按国家
  • MEA：国家分析
    • 南非神经内分泌肿瘤药物
    • 关于沙特阿拉伯神经内分泌肿瘤的治疗
    • 阿联酋神经内分泌肿瘤的治疗

第 12 章市场动态

  • 司机
    • 新药的开发和批准
    • 人工智能 (AI) 在治疗技术中的应用
    • 政府和公司加大力度
  • 做
    • 昂贵的医疗费用
    • 治疗的伴随副作用
    • 严格的监管框架

第13章市场趋势与发展

  • 未来患者援助计划 (PAP)
  • 正在进行的临床试验和研发计划
  • 采用下一代测序技术

第14章竞争格局

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（As Reported）
  • Recent Developments
  • SWOT Analysis
    • F Hoffmann-La Roche AG
    • Bristol-Myers Squibb Co
    • Eli Lilly & Co
    • Novartis AG
    • Pfizer Inc
    • Amgen Inc
    • Exelixis Inc
    • Teva Pharmaceutical Industries Ltd
    • AVEO Pharmaceuticals Inc
    • Hutchison MediPharma Ltd

第15章 战略建议

简介目录
Product Code: 7606

Global neuroendocrine tumor treatment market is anticipated to escalate in the forecast period, 2024-2028. This can be attributed to the rising prevalence of neuroendocrine tumors across the globe. The incidence of neuroendocrine tumors has increased notably in the past three to four decades, according to an article published in the Journal of Cancers in April 2022, titled "Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)". Neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC) disease, multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), and Von Hippel-Lindau syndrome (VHL) can be owed to the increased prevalence of neuroendocrine tumor (NET). In the United States, more than 12,000 people are diagnosed with a neuroendocrine tumor per year, and around 175,000 people are living with it, according to the most recent American Society of Clinical Oncology Neuroendocrine Tumor Statistics, which was updated in February 2022.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center. The high frequency of neuroendocrine cancer patients worldwide is anticipated to contribute to the market's growth.

The treatment techniques for neuroendocrine tumors such as targeted therapy, radionuclide treatment, somatostatin analogs, immunotherapy, CAR-T-Cell therapy, INF α, trans arterial treatment, vaccines, bispecific antibodies, and cytotoxic chemotherapy of highly differentiated and low differentiated G1 and G2 GEP neuroendocrine tumor treatments (NETs) have also observed innovations in the past few years. This advancement in treatment techniques has led to a robust improvement in the growth of the neuroendocrine tumor treatment market. Furthermore, there has been a severe betterment in the survival rates of all neuroendocrine tumor treatments, according to a study published in the JAMA Oncology Journal in 2017.

Increased Government Initiatives

The governments of many developed nations like the United States are raising funds for research in cancer to assist in its diagnosis as well as treatment. The government is also funding numerous clinical trials to encourage companies to develop successful and effective cancer treatments. For instance, with federal government funding in cancer research, which is essential to assuring a future free of cancer, the American Institute for Cancer Research has financed almost USD110 million in research as of April 2021. Additionally, under the 2021 Rare Cancers, Rare Illnesses and Unmet Need (RCRDUN) grant opportunity, The Department of Health of the Commonwealth of Australia January 2022 announced the availability of a grant for the study of rare cancers and rare diseases for USD 63.4 million. Moreover, for the project "Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumor: the AUS-NET Trial," Flinders University specifically obtained USD 2,374,220.10 in funding. Also, USD 1.5 million was invested by The Neuroendocrine Tumor Research Foundation (NETRF) for the development of Peptide Receptor Radionuclide Therapy (PRRT), an advanced radiation therapy.

Steps were taken by the Companies

Plenty of players in the industry are also adopting strategies, for example, partnerships and collaborations, novel product launches, agreements related to distribution along with a regional extension to establish their market position. For example, Boehringer Ingelheim GmbH declared an investment of USD 270 million for the construction of a new Biologicals Development Center (BDC) that will be specializing in immunology as well as immune-oncology in June 2018. Additionally, Novartis AG, in January 2018 announced to buy of all the ordinary shares from its subsidiary group Novartis Groupe France S.A., also inclusive of Advanced Accelerator Applications S.A. (AAA).

Recent Developments

  • Aerium Therapeutics Inc began operations in June 2022 with USD26.50 million (EUR 25 million) funding for systemic targeted radiation therapy and the diagnosis of low- and high-grade neuroendocrine tumors.
  • Ipsen SA invested in a brand-new, cutting-edge electronic autoinjector in March 2022 for Somatuline Autogel/Somatuline Depot (lanreotide) to advance innovation in the category and enhance patient administration and injection experiences. The autoinjector is intended to enhance the patient experience for those dealing with carcinoid syndrome, acromegaly, or gastroenteropancreatic neuroendocrine tumors.
  • Belzutifan (Welireg), a hypoxia-inducible factor inhibitor suitable for adults suffering from von Hippel-Lindau disease received approval from FDA in August 2021.

Market Segmentation

Global neuroendocrine tumor treatment market is segmented based on a product analysis, site analysis, end user, region, and company. Based on a product analysis, the market can be categorized into somatostatin analogs (SSA), targeted therapy, and others. Based on site analysis, the market can be divided into lungs, pancreas, colon, small intestine, and others. Based on end users, the market can be segmented into hospitals & clinics, ambulatory care centers, and others.

Company Profiles

Some of the major competitors operating in the global neuroendocrine tumor treatment market are F Hoffmann-La Roche AG, Bristol-Myers Squibb Co, Eli Lilly & Co, Novartis AG, Pfizer Inc, Amgen Inc, Exelixis Inc, Teva Pharmaceutical Industries Ltd, AVEO Pharmaceuticals Inc, and Hutchison MediPharma Ltd among others.

Report Scope:

In this report, global neuroendocrine tumor market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuroendocrine Tumor Treatments Market, By Product Analysis:

  • Somatostatin Analogs (SSA)
  • Targeted Therapy
  • Others

Neuroendocrine Tumor Treatments Market, By Site Analysis:

  • Lungs
  • Pancreas
  • Colon
  • Small Intestine
  • Others

Neuroendocrine Tumor Treatments Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Neuroendocrine Tumor Treatments Market, By Region:

  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • North America
    • United States
    • Mexico
    • Canada
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global neuroendocrine Tumor treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Site Analysis
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Neuroendocrine Tumor Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 6.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 6.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Product Analysis
    • 6.3.2. By Site Analysis
    • 6.3.3. By End User
    • 6.3.4. By Region

7. Asia-Pacific Neuroendocrine Tumor Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 7.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 7.2.4. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Analysis
        • 7.3.1.2.2. By Site Analysis
        • 7.3.1.2.3. By End User
    • 7.3.2. India Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Analysis
        • 7.3.2.2.2. By Site Analysis
        • 7.3.2.2.3. By End User
    • 7.3.3. Japan Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Analysis
        • 7.3.3.2.2. By Site Analysis
        • 7.3.3.2.3. By End User
    • 7.3.4. South Korea Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Analysis
        • 7.3.4.2.2. By Site Analysis
        • 7.3.4.2.3. By End User
    • 7.3.5. Australia Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Analysis
        • 7.3.5.2.2. By Site Analysis
        • 7.3.5.2.3. By End User

8. Europe Neuroendocrine Tumor Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 8.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 8.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Analysis
        • 8.3.1.2.2. By Site Analysis
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Analysis
        • 8.3.2.2.2. By Site Analysis
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Analysis
        • 8.3.3.2.2. By Site Analysis
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Analysis
        • 8.3.4.2.2. By Site Analysis
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Analysis
        • 8.3.5.2.2. By Site Analysis
        • 8.3.5.2.3. By End User

9. North America Neuroendocrine Tumor Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 9.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 9.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Neuroendocrine Tumor Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Analysis
        • 9.3.1.2.2. By Site Analysis
        • 9.3.1.2.3. By End User
    • 9.3.2. Mexico Neuroendocrine Tumor Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Analysis
        • 9.3.2.2.2. By Site Analysis
        • 9.3.2.2.3. By End User
    • 9.3.3. Canada Neuroendocrine Tumor Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Analysis
        • 9.3.3.2.2. By Site Analysis
        • 9.3.3.2.3. By End User

10. South America Neuroendocrine Tumor Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 10.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 10.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neuroendocrine Tumor Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Analysis
        • 10.3.1.2.2. By Site Analysis
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Neuroendocrine Tumor Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Analysis
        • 10.3.2.2.2. By Site Analysis
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Neuroendocrine Tumor Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Analysis
        • 10.3.3.2.2. By Site Analysis
        • 10.3.3.2.3. By End User

11. Middle East and Africa Neuroendocrine Tumor Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 11.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 11.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Neuroendocrine Tumor Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Product Analysis
        • 11.3.1.2.2. By Site Analysis
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Neuroendocrine Tumor Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Product Analysis
        • 11.3.2.2.2. By Site Analysis
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Neuroendocrine Tumor Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Product Analysis
        • 11.3.3.2.2. By Site Analysis
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
    • 12.1.1. Developments and Approval of Novel Drugs
    • 12.1.2. Use of Artificial Intelligence (AI) in Treatment Techniques
    • 12.1.3. Increased Government and Company's' Initiatives
  • 12.2. Challenges
    • 12.2.1. High Cost of the Treatment
    • 12.2.2. Associated Side Effects of the Treatment
    • 12.2.3. Stringent Regulatory Framework

13. Market Trends & Developments

  • 13.1. Upcoming Patient Assistance Programs (PAPs)
  • 13.2. Ongoing Clinical Trials and R&D Programs
  • 13.3. Adoption of Next-Generation Sequencing Techniques

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As Reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. F Hoffmann-La Roche AG
    • 14.6.2. Bristol-Myers Squibb Co
    • 14.6.3. Eli Lilly & Co
    • 14.6.4. Novartis AG
    • 14.6.5. Pfizer Inc
    • 14.6.6. Amgen Inc
    • 14.6.7. Exelixis Inc
    • 14.6.8. Teva Pharmaceutical Industries Ltd
    • 14.6.9. AVEO Pharmaceuticals Inc
    • 14.6.10. Hutchison MediPharma Ltd

15. Strategic Recommendations